Open AccessA Randomized Study of H3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer's Dementia1
Author(s) -
George M. Haig,
Yili Pritchett,
Andreas Meier,
Ahmed A. Othman,
Coleen Hall,
Laura M. Gault,
Robert Lenz
Publication year - 2014
Publication title -
journal of alzheimer's disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.677
H-Index - 139
eISSN - 1875-8908
pISSN - 1387-2877
DOI - 10.3233/jad-140291
Subject(s) - donepezil , placebo , dementia , clinical endpoint , medicine , adverse effect , randomized controlled trial , alzheimer's disease , antagonist , psychology , disease , receptor , pathology , alternative medicine
ABT-288, a highly selective histamine-3 receptor antagonist, demonstrated efficacy across several preclinical cognitive domains, and safety in healthy subjects and elderly volunteers.